US 10,519,146 B2 · KRAS G12C inhibitors and methods of using the same

KRAS G12C inhibitors and methods of using the same

AssigneeAmgen Inc.

InventorsBrian Alan Lanman, Jian Chen, Anthony B. Reed, Victor J. Cee, Longbin Liu, David John Kopecky, Patricia Lopez, Ryan Paul Wurz, Thomas T. Nguyen, Shon Booker, Nobuko Nishimura, Youngsook Shin, Nuria A. Tamayo, John Gordon Allen, Jennifer Rebecca Allen

Life of this patent

Estimating the term…

Abstract

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Claims33

Dependent claims

A compound having a structure selected from:

or a stereoisomer thereof, an atropisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, or a pharmaceutically acceptable salt of the atropisomer thereof.

Dependencies are inferred from the claim text.

Facts

Application

15/984,855Filed 21 May 2018 · us provisional application

Priority

22 May 2017

Published

US 2018/0334454 A122 Nov 2018

Granted

31 Dec 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification29 codes

C07D 417/04
Containing two hetero rings: directly linked by a ring-member-to-ring-member bond
A61K 31/416
1,2-Diazoles: condensed with carbocyclic ring systems, e.g. indazole
A61K 31/454
Containing further heterocyclic ring systems: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/496
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: non-condensed piperazines…